4D Molecular Therapeutics (FDMT) Stock Overview
A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
FDMT Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
4D Molecular Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.10 |
| 52 Week High | US$12.34 |
| 52 Week Low | US$2.47 |
| Beta | 2.93 |
| 1 Month Change | 13.87% |
| 3 Month Change | 34.67% |
| 1 Year Change | 289.96% |
| 3 Year Change | -40.06% |
| 5 Year Change | -72.16% |
| Change since IPO | -75.06% |
Recent News & Updates
Recent updates
4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop
Dec 194D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression
Feb 18Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth
Nov 24
4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure
Oct 044D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans
Aug 104D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data
Jul 194D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution
Apr 294D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
Feb 064D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
Jan 254D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 12We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Nov 08Shareholder Returns
| FDMT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.5% | -0.7% | 1.2% |
| 1Y | 290.0% | 45.0% | 32.8% |
Return vs Industry: FDMT exceeded the US Biotechs industry which returned 45% over the past year.
Return vs Market: FDMT exceeded the US Market which returned 32.8% over the past year.
Price Volatility
| FDMT volatility | |
|---|---|
| FDMT Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: FDMT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: FDMT's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 196 | David Kirn | www.4dmoleculartherapeutics.com |
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company’s lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease.
4D Molecular Therapeutics, Inc. Fundamentals Summary
| FDMT fundamental statistics | |
|---|---|
| Market cap | US$516.13m |
| Earnings (TTM) | -US$140.11m |
| Revenue (TTM) | US$85.21m |
Is FDMT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FDMT income statement (TTM) | |
|---|---|
| Revenue | US$85.21m |
| Cost of Revenue | US$192.50m |
| Gross Profit | -US$107.29m |
| Other Expenses | US$32.82m |
| Earnings | -US$140.11m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.74 |
| Gross Margin | -125.91% |
| Net Profit Margin | -164.43% |
| Debt/Equity Ratio | 0% |
How did FDMT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/09 02:19 |
| End of Day Share Price | 2026/04/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
4D Molecular Therapeutics, Inc. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |
| Konstantinos Biliouris | BMO Capital Markets Equity Research |